Phio Pharmaceuticals AI Stock Analysis
Want to see PHIO full AI Analyst Report?
Phio Pharmaceuticals (PHIO) AI Stock Analysis
Phio Pharmaceuticals
(NASDAQ:PHIO)
Overall score is held down primarily by weak financial performance (no revenue, widening losses, and increasing cash burn implying continued financing risk) and bearish technicals (price below key moving averages with negative MACD). Positive pipeline milestones provide some offset, but do not outweigh the current financial and trend headwinds.
Phio Pharmaceuticals (PHIO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.21M
- Dividend Yield
- ―
- Average Volume (3M)
- 119.52K
- Price to Earnings (P/E)
- -0.6
- Beta (1Y)
- 2.12
- Revenue Growth
- ―
- EPS Growth
- 43.66%
- Country
- US
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Phio Pharmaceuticals Business Overview & Revenue Model
Company Description
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center...
How the Company Makes Money
Phio Pharmaceuticals is a clinical-stage company and does not have a product portfolio marketed for commercial sale; therefore, recurring product revenue from drug sales is null. Its ability to generate revenue, when it occurs, is typically tied to n...
Phio Pharmaceuticals Financial Statement Overview
Summary
Financial performance is weak: the company is pre-revenue ($0 revenue across periods), losses have widened in TTM (net loss about -$14.7M vs -$8.7M in 2025), and cash burn increased (operating cash flow about -$12.4M TTM vs -$8.0M in 2025). Low debt reduces leverage risk, but shrinking/volatile equity and persistent negative free cash flow point to ongoing financing dependence.
Income Statement
12Very NegativeBalance Sheet
48NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1.48M | -4.62M | -3.64M | -6.33M | -7.01M | -8.89M |
| EBITDA | -15.06M | -8.70M | -7.12M | -10.64M | -11.29M | -13.21M |
| Net Income | -14.67M | -8.70M | -7.15M | -10.83M | -11.48M | -13.29M |
Balance Sheet | ||||||
| Total Assets | 11.32M | 21.49M | 5.74M | 9.36M | 12.81M | 25.17M |
| Cash, Cash Equivalents and Short-Term Investments | 10.61M | 21.03M | 5.38M | 8.49M | 11.78M | 24.06M |
| Total Debt | 0 | 0 | 0 | 35.00K | 170.00K | 295.00K |
| Total Liabilities | 2.70M | 1.34M | 1.01M | 1.63M | 1.97M | 3.24M |
| Stockholders Equity | 8.62M | 20.15M | 4.72M | 7.73M | 10.84M | 21.93M |
Cash Flow | ||||||
| Free Cash Flow | -12.40M | -7.99M | -7.11M | -10.75M | -12.25M | -11.91M |
| Operating Cash Flow | -12.40M | -7.98M | -7.11M | -10.75M | -12.13M | -11.86M |
| Investing Cash Flow | 3,000 | -12.00K | 8,000 | -5,000 | -121.00K | -51.00K |
| Financing Cash Flow | 12.30M | 23.64M | 4.00M | 7.41M | -26.00K | 21.72M |
Phio Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHIO, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 0.93, and below the 200-day MA of 1.07, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 30.54 is Neutral, neither overbought nor oversold. The STOCH value of 21.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHIO.
Phio Pharmaceuticals Risk Analysis
Phio Pharmaceuticals disclosed 23 risk factors in its most recent earnings report. Phio Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksPhio Pharmaceuticals Peers Comparison
Overall Rating
PASG50Neutral
PHIO43Neutral
XCUR42Neutral
SNTI39Underperform
INAB38Underperform
KALA28Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $13.29M | -0.38 | -377.94% | ― | ― | 28.49% | |
| 43Neutral | $8.99M | -0.59 | -101.48% | ― | ― | 43.66% | |
| 42Neutral | $7.00M | -0.83 | -237.91% | ― | ― | 23.05% | |
| 39Underperform | $4.24M | -0.08 | -1539.97% | ― | ― | 80.28% | |
| 38Underperform | $8.82M | -0.70 | -93.66% | ― | ― | 81.16% | |
| 28Underperform | $2.47M | -0.00 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PHIO | Phio Pharmaceuticals | 0.75 | -0.52 | -40.79% | |
| KALA | Kala Bio, Inc. | 3.83 | -1029.37 | -99.63% | |
| XCUR | Exicure | 1.07 | -2.66 | -71.31% | |
| PASG | Passage Bio, Inc. | 4.13 | -4.39 | -51.53% | |
| INAB | In8bio, Inc. | 0.82 | -0.82 | -50.24% | |
| SNTI | Senti Biosciences, Inc. | 0.14 | -1.57 | -92.05% |
Phio Pharmaceuticals Corporate Events
Phio Pharmaceuticals Advances PH-762 With Commercial-Scale cGMP Batch
PositiveOn October 13, 2026, Phio Pharmaceuticals announced it had successfully completed and released its first commercial-scale cGMP batch of PH-762 drug substance, manufactured under current Good Manufacturing Practice regulations and ICH Q7 guidelines. T...
Phio Pharmaceuticals Expands Equity Incentive Pool at Meeting
NeutralPhio Pharmaceuticals held its 2026 Annual Meeting of Stockholders via live webcast on September 28, 2026, where shareholders approved an amendment to its 2020 Long Term Incentive Plan, increasing the number of shares available for issuance by 1,500,0...
Phio Advances PH-762 Toward Phase 2b Skin Cancer Trial
PositiveOn September 14, 2026, Phio Pharmaceuticals announced a key development milestone for its lead candidate PH-762 following formal completion of a Phase 1b trial in skin cancers. The company submitted a meeting request and comprehensive briefing packag...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
